🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "huge turning point" in the battle against increasingly resistant strains of the pathogen, according to researchers.

A Worldwide Health Concern

Gonorrhoea infections are increasing globally, with figures suggesting in excess of 82 million infections each year. Especially elevated rates are reported in the African continent and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an important and timely advancement in the face of increasing worldwide cases, increasing antimicrobial resistance and the very limited available drugs at this time.”

Public health authorities are particularly alarmed about the rise in drug-resistant strains. The WHO has listed it as a "priority pathogen". Recent surveillance revealed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Approval

One new antibiotic, marketed under the name a brand name, was approved by the US FDA in mid-December for treating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Scientists hope that focused deployment of this new drug will help delay the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, also received approval in concurrent days. This drug, which is also used to treat UTIs, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a new, not-for-profit approach for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through.

“This milestone represents a significant shift in the treatment of superbug gonorrhoea, which until now has been evolving faster than antibiotic development.”

Clinical Trial Results and Global Access

According to data released by a prominent scientific publication, zoliflodacin eradicated the vast majority of cases of the STI. This places it at an equal footing with the current standard treatment, which combines an injection and a pill. The research enrolled nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the rights to license and sell the drug in many low-income and middle-income countries.

Doctors on the front lines have voiced hope. The availability of a easy-to-administer therapy of this kind is seen as a "revolutionary step" for gonorrhoea control. This is viewed as essential to alleviate the strain of the disease for patients and to stop the proliferation of extremely resistant gonorrhoea globally.